Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% [Yahoo! Finance]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Yahoo! Finance
The top 6 shareholders, including FMR LLC, Fairmount Funds Management LLC, and VR Adviser, LLC, own 50% of the company, giving them significant influence over the company's share price. Insiders, including CEO Lawrence Klein, own 2.4% of the company's shares, while the general public holds a 13% stake. The company's institutional ownership suggests a certain degree of credibility in the investment community, but it's essential to consider other factors, such as past earnings trajectory and analyst forecasts, to understand the company's future performance. Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence over the company's share price The top 6 shareholders own 50% of the company Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company If you want to know who really controls Oruka Therapeutics, Inc. ( NASDAQ:ORKA ), then you'll have to look at the makeup of its
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyGlobeNewswire
- Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswire
ORKA
Sec Filings
- 12/19/24 - Form 8-K
- 11/27/24 - Form EFFECT
- 11/21/24 - Form SC
- ORKA's page on the SEC website